ID: ALA2336005

Max Phase: Preclinical

Molecular Formula: C24H23N3O2S

Molecular Weight: 417.53

Molecule Type: Small molecule

Representations

Canonical SMILES:  Oc1cccc(Nc2ccnc3cc(-c4cccc(CN5CCOCC5)c4)sc23)c1

Standard InChI:  InChI=1S/C24H23N3O2S/c28-20-6-2-5-19(14-20)26-21-7-8-25-22-15-23(30-24(21)22)18-4-1-3-17(13-18)16-27-9-11-29-12-10-27/h1-8,13-15,28H,9-12,16H2,(H,25,26)

Standard InChI Key:  ZCWXCBKGPJOAFQ-UHFFFAOYSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Small molecule

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 417.53

Molecular Weight (Monoisotopic): 417.1511

AlogP: 5.24

#Rotatable Bonds: 5

Polar Surface Area: 57.62

Molecular Species: NEUTRAL

HBA: 6

HBD: 2

#RO5 Violations: 1

HBA (Lipinski): 5

HBD (Lipinski): 2

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 9.70

CX Basic pKa: 6.76

CX LogP: 4.52

CX LogD: 4.43

Aromatic Rings: 4

Heavy Atoms: 30

QED Weighted: 0.46

Np Likeness Score: -1.32

References

1. Gao M, Duan L, Luo J, Zhang L, Lu X, Zhang Y, Zhang Z, Tu Z, Xu Y, Ren X, Ding K, Ding K..  (2013)  Discovery and optimization of 3-(2-(Pyrazolo[1,5-a]pyrimidin-6-yl)ethynyl)benzamides as novel selective and orally bioavailable discoidin domain receptor 1 (DDR1) inhibitors.,  56  (8): [PMID:23521020] [10.1021/jm301824k]

2. Li Y, Lu X, Ren X, Ding K..  (2015)  Small molecule discoidin domain receptor kinase inhibitors and potential medical applications.,  58  (8): [PMID:25569119] [10.1021/jm5012319]

3.  (2015)  Anti-inflammatory compound having inhibitory activity against multiple tyrosine kinases and pharmaceutical composition containing same, 

Source

Source(2):

• Scientific Literature
• BindingDB Database